Principal Investigator: Damon Reed, MD (Moffitt Cancer Center)
An FDA approved clinical trial focused on relapsed or refractory solid tumors in children. Solid tumors account for 60% of all childhood malignancies and unlike other childhood cancers, minimal improvement in survival has been seen in the past 20 years. These disappointing results have prompted NPCF to find new agents in the fight against this disease.
Metformin is an oral anti-diabetes medication. Recent data from research experiments and analyses of previous data suggest that Metformin has anti-cancer activity. The drugs vincristine, irinotecan and temozolomide, also known as VIT, are a combination of chemotherapies that have different ways of working and different side effects. This combination has been shown to be safe and well tolerated in children with solid tumors. This trial is evaluating the tolerability and safety of increasing doses of Metformin in combination with vincristine, irinotecan, and temozolomide in children with solid tumors.